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Obstetric Haemorrhage is the leading cause of maternal death globally (1) and the third 
leading cause of death in South Africa (2). Concern has been expressed in South Africa that 
bleeding associated with caesarean delivery (CD) accounts for one-third of haemorrhage 
deaths and this has increased over the last ten years (3). The underlying cause of bleeding 
at CD is commonly uterine atony, and the majority of the CDs were performed at district 
hospitals (2,3,4). The Saving Mothers Reports describe inadequate use and documentation 
of uterotonics to prevent or treat bleeding at CD and have promoted the development of a 
standardised national protocol. While there is international agreement on the dosage and 
administration route for oxytocin to prevent OH after vaginal delivery, there is lack of 
consensus or standardisation of protocols for its prophylactic use at CD, with marked 
differences between country and facility protocols. Anaesthetists are concerned about the 
hypotensive effect of high dose intravenous boluses of oxytocin, particularly in women under 
spinal anaesthesia, and some maternal mortalities in the United Kingdom have been partially 
attributed to this (5). Hence it is important to balance safety with efficacy by promoting the 
lowest effective doses to minimise side effects but enable uterine contraction.  
Aim  
The aim of this study was to perform a clinical audit of the documented use of uterotonics at 
CD at MMH to see how it adheres to the national protocol; and as a secondary outcome to 
measure the rate of haemorrhage at CD.  
Methods  
This was a retrospective folder review of women who delivered by CD at MMH during the 
months of June and July 2017, including both elective and emergency operations. 
Information was obtained from women’s folders kept in the medical records department, 
using especially designed data extraction sheets. Data analysis was by simple descriptive 
statistics. 
Results  
Three hundred and nineteen (319) folders from the study period were interrogated. This 
included 239 emergency CDs (75%) and 80 elective CDs (25%). They were all performed by 
obstetric registrars or medical officers with 89% being done under spinal anesthesia. 
Prophylactic oxytocin boluses at CD were given in 302 (94.7%) women but there was no 
documentation of its use in 17 (5.3%). One of the 302 women had a high dose IV bolus (7.5 
IU) but the remainder had boluses below 5 IU. There were 75 women (23.5%) patients who 
received the national recommended dose of 2.5 IU IVI while 227 (71.1%) received 
vi 
 
alternative low dose boluses which were all less than 5 IU. The dose most commonly given 
was 3 IU; to 169 patients (53%) as a single or divided dose. There was wide variation in the 
dosage of prophylactic infusions with only 18 (5.6%) patients receiving the recommended 
intraoperative 7.5 IU infusion, while 221 (66.5%) received alternate infusion doses. Only 49 
(15%) were discharged from theatre recovery to the postnatal ward with a prophylactic 
infusion running. In total 65 (20.4%) of the women received a 20 IU oxytocin infusion but it 
was unclear whether this was for prophylaxis or treatment. No intramuscular doses of 
oxytocin or syntometrine were given for prophylaxis. Among the 319 CDs, 13 (4.1%) had 
documented blood loss over 1000 ml and 24 (7.5%) had uterine atony reported by the 
surgeon. The most common treatment was 20 IU infusion followed by misoprostol (13 
women), syntometrine (three women) and tranexamic acid (one woman). Additional surgical 
measures required were B-Lynch compression suture for one, and haemostatic sutures for 
two. There were no re-look laparotomies or hysterectomies during the study period and there 
were no major morbidity or mortalities from either CD or from anaesthetic complications.  
Discussion  
Low dose bolus oxytocin and infusion is widely used at CD post fetal delivery at MMH, 
although the dose of 3 IU was most commonly used in contrast to the recommended 2.5 IU 
in the national protocol. There was variation in the usage and dosage of prophylactic 
oxytocin infusion. The rate of PPH in the subjects was low (4.1%) with the low dose 
prophylactic regimens used, suggesting that they were effective, although this may also 
have been contributed to by the skill of the surgeons. Consensus is needed among 
anaesthetists and standardisation of protocols on oxytocin prophylaxis at CD, particularly for 
training doctors working in district hospitals. Repeating this audit in district hospitals where 
there are higher CD case fatality rates would be important to shed light on practice in such 
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Chapter 1:  Introduction 
1.1 Background 
Obstetric haemorrhage (OH) remains an important cause of maternal morbidity and mortality 
globally. It is estimated that up to 800 women die per day worldwide as a consequence of 
pregnancy and childbirth, with haemorrhage accounting for two-thirds of these deaths (3). Most 
of this bleeding is related to uterine atony. In South Africa, OH has featured among the top three 
causes of maternal mortality in recent triennial publications of the Saving Mothers Reports 
which describe findings of the Confidential Enquiry into Maternal Deaths in South Africa (CEMD) 
(2,4,5). An important component of this problem is bleeding at caesarean delivery (CD) which 
has increased markedly in the last ten years as a cause of maternal death. Bleeding during or 
after caesarean delivery (BLDACD) accounts for nearly a third of deaths related to obstetric 
haemorrhage (221 deaths during 2011-2013) and this occurs mainly at level one and two 
hospitals (6). The mortality rate due to BLDACD is markedly lower in the Western Cape 
compared to the rest of South Africa and this is reflected in the statistics of Mowbray Maternity 
Hospital (MMH) where in three years there have been two deaths from this condition out of 
15000 CDs. Nearly 5000 CDs are performed annually at MMH with a case fatality rate of 16.6 
per 10000 CS compared to 33.6 in South Africa for a similar time period. 
A common cause of CD associated bleeding is uterine atony. One of the measures put in place 
to prevent or treat bleeding at CD includes the routine and therapeutic use of various uterotonic 
drugs to aid uterine contractility. There has been widespread discussion and conflicting views 
between obstetricians and anaesthetists about safe but effective doses particularly of oxytocin, 
but also of misoprostol and ergometrine. Obstetricians promote the use of prophylactic oxytocin 
at CD, but anaesthetists are concerned about the potential of high dose  intravenous boluses to 
cause hypotension (7,8). The 2011-2013 triennial Saving Mothers Report  reports that 
inadequate doses of uterotonics were administered in many of the deaths from BLDACD, but 
also that in many case files there was no documentation concerning if and what uterotonic was 
administered (2). Protocols have been put in place, disseminated and published by the National 
Committee on Confidential Enquiry into Maternal Deaths (NCCEMD) for the Department of 
Health on the prevention and management of BLDACD (9). These include an updated  
consensus policy on recommended use of uterotonics at CD (10).   
1.2 Rationale for current study 
There is a dearth of studies that have audited uterotonic use in maternity units especially, in 
Sub-Saharan Africa or other low resource settings where the burden of OH is greatest. There is 
not much literature addressing the compliance of maternity units to set protocols for the 
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prophylaxis and treatment of PPH, particularly at CD. An audit of oxytocin use in a tertiary level 
hospital in Botswana found that there were no standardised protocols for oxytocin use at CD 
and as a result prescribing practice differed significantly among the healthcare workers, with 
some giving as high as 20 IU intravenous bolus of oxytocin (11). 
The other concern raised by the Saving Mothers Report (2011-2013) was that documentation 
was poor, which made it difficult to properly assess whether uterotonics were administered as 
per protocols. A study on peripartum hysterectomy in the UK found that some women who had 
a hysterectomy as treatment for PPH did not have any uterotonic administered to them, while 
another subset (23%) of women in the same study had only one uterotonic given before 
hysterectomy (12). This may reflect lack of documentation as in South Africa, or that it was not 
given or not thought to be indicated.   
The question for this study is whether MMH is documenting the administration of uterotonics at 
CD and adhering to the recommended protocols for their use in prophylaxis and treatment of 
PPH. The hypothesis for the current study is that MMH is using adequate uterotonic therapy 






Chapter 2. Literature Review 
2.1 Introduction 
Maternal mortality is defined by the World Health Organization (WHO) as the death of a woman 
while pregnant or within 42 days after termination of a pregnancy, no matter how long the 
gestation was or where the pregnancy was located, from any cause related to or aggravated by 
the pregnancy or its management but not from accidental or incidental causes (13). Maternal 
mortality has for a long time been a bane of many health systems globally. The developed world 
has led the way in reducing the scourge of mothers dying in delivery, while the developing 
countries continue to report ongoing maternal deaths. Estimates by the WHO show that an 
alarming 99% (302,000) of all maternal deaths in the world in 2015 occurred in developing 
countries, with the Sub-Saharan African region alone accounting for 66% of the deaths (14), 
many of which were preventable. 
The impact of maternal deaths on society is dire and the effects are felt and are more 
pronounced in the developing world than the developed world (15). Studies in East Africa have 
shown that the consequences of a maternal death or disabling injury secondary to pregnancy 
complications not only impact the immediate grieving family but the community as well. The 
impact is felt not only in the immediate future but for generations to come (15). Some of the 
issues include financial instability in the household and for the relatives who have to take over 
the care of orphaned children, which comes with great financial burden. There is also disruption 
of schooling and education and increased mortality among children whose mothers have died, 
related to difficulty managing the household by the bereaved fathers. Similar findings were 
found in a study from rural China (16). 
Efforts have previously been made to address maternal deaths globally, for example, the 1987 
Safe Motherhood Conference, and the 1995 Beijing World Congress on Women, but they have 
had little impact. The issue of maternal and reproductive health was brought into the spotlight 
when the United Nations met in the groundbreaking Millennium Summit in the year 2000 and 
proclaimed the Millennium Development Goals, one of which, Goal 5, was the improvement of 
maternal health (17). The target was reduction of maternal deaths by 75% by the year 2015. 
Overall maternal deaths decreased from 532,000 in 1990 to 303,000 in 2015. Global MMR 
declined by 45% with slowest improvements in countries of Sub-Saharan Africa (1,18). Only 
eight nations managed to achieve a 75% reduction in maternal deaths, of which one, Rwanda, 
is on the African continent (3).  
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As 2015 came to an end, a transition to a new set of United Nations goals, commonly known as 
the Sustainable Development Goals (SDG), came into being. There are 17 SDGs which are tied 
to 169 targets. Goal 3 of the SDGs is geared at ensuring healthy lives and the promotion of well-
being for all. With respect to maternal mortality, the target is reduction by the year 2030 of the 
global MMR to 70 deaths per 100,000 live births, with no country having an MMR of more than 
140 (1). 
Of the many causes of maternal death and severe morbidity, obstetric haemorrhage is the 
leading cause of maternal deaths globally. A reported 127,000 women die yearly from obstetric 
haemorrhage and the rates are 14 times higher in developing countries compared to developed 
countries. The 2011-2013 triennial report on maternal deaths from the United Kingdom (UK) 
indicated that 13 women died as a result of OH (19); this compares with 684 deaths in South 
Africa in the same time period (2). The concerning aspect of deaths resulting from obstetric 
haemorrhage in South Africa is that the majority (89%) during 2011-2013 were preventable. 
Postpartum haemorrhage (PPH) is the most common type of obstetric haemorrhage. The 
number of women dying from PPH is greatest in low resource settings compared to well-
resourced countries where PPH tends to be a more frequent cause of morbidity than mortality 
(20). In Uganda, PPH causes 25% of all maternal deaths, whereas in the United States it is the 
fourth leading cause of maternal death, accounting for 13.4% of maternal deaths. PPH 
occurring at or after CD has been implicated in a rising number of maternal deaths in South 
Africa. In three successive triennial reports a steady increase in deaths at or during CD has 
been reported, with 221 deaths in the last report (2011-2013), compared to 180 in the previous 
report period (5). Caesarean delivery rates are increasing globally and in South Africa, with the 
potential to increase the problem of bleeding at CD. This is particularly relevant in South Africa 
where CDs are performed at all levels of care, including by non-specialist doctors at district 
hospitals. 
Uterine atony has been identified as a leading cause of PPH after vaginal delivery and also at 
CD. Uterine atony is defined as the failure of the uterus to have sustained, proper haemostatic 
contractions. The causes of uterine atony include uterine over-distension (multiple gestation), 
intrinsic uterine dysfunction (prolonged labour), retained products of conception, abnormal 
placentation and iatrogenic causes such as volatile anaesthetics. In one large population based 
retrospective study of 649,000 childbirths (vaginal, instrumental, elective and emergency CD) 
from Ireland, uterine atony was responsible for 75.7% of PPH diagnoses (21). Other common 
causes include genital tract trauma and rarely, coagulation disorders.  
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The routine use of uterotonics at delivery has been advocated by many international societies 
and organisations as one of the measures for combating uterine atony and thus ameliorating the 
risk of PPH. However, it has been noted by several investigators that uterotonics are not 
routinely administered to all patients which thus puts parturients at risk for PPH (2,12). 
Documentation of uterotonic use at CD is a particular problem. According to the authors of the 
Saving Mothers Report 2011-2013, several issues regarding the administration of uterotonics at 
CD were identified from folder reviews of maternal deaths attributed to PPH:  
a)  poor documentation of whether any uterotonics were given;  
b)  inadequate doses of uterotonics were administered,  
c) poor documentation of the route, timing or if any repeat doses were given; and  
d)  inadequate documentation as to whether any additional uterotonics were given.  
There are several uterotonic medications available to healthcare workers managing patients at 
delivery in South Africa.  
2.2 Oxytocin 
Oxytocin is a neuropeptide that was discovered and synthesised in the early 1950s. It is 
produced in the paraventricular nuclei in the hypothalamus and released in a pulsatile manner 
by the posterior pituitary into the circulation where it binds to its receptor on uterine muscle cells 
and acts via intracellular messenger systems to increase the concentration of intracellular 
calcium. Intracellular calcium activates calmodulin and myosin light chain kinase leading to 
uterine muscle contraction. Oxytocin is widely distributed in the extracellular space and is 
metabolised by the gastrointestinal enzyme chymotrypsin. In the pregnant subject oxytocinase 
is produced early in the pregnancy and metabolises oxytocin. 
Prophylactic uterotonic (oxytocin) use after vaginal delivery is a well-established obstetric 
practice with robust evidence to back up its use (22). Oxytocin has been found to reduce the 
risk of PPH by at least 40% and is the drug of choice when compared to placebo following 
vaginal delivery (23). Thus 10 IU IMI oxytocin is recommended by the WHO and the South 
African National Department of Health (DOH) as the uterotonic of choice for the prophylaxis of 
postpartum haemorrhage after vaginal delivery (22,24). However, the optimal route of 
administration and dose of prophylactic oxytocin at CD where there is intravenous access, has 
been less studied. Globally there are wide variations in the use of oxytocin at CD and even 
where guidelines exist, surveys among obstetric practitioners have revealed inconsistencies in 
usage (25). 
2.2.1 Haemodynamic effects of oxytocin 
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Concerns have been raised about the side effect profile (26) of oxytocin by the anaesthetic 
community, especially its effects on haemodynamic instability and water intoxication. 
Intravenous boluses of oxytocin are known to cause hypotension especially when 10 IU 
oxytocin IVI or more are given rapidly as a bolus (26). Oxytocin causes hypotension by 
transiently relaxing vascular smooth musculature via triggering the nitric oxide pathway. This 
results in the mean arterial blood pressure decreasing and associated with a reflex tachycardia 
and increase in cardiac output which are easily tolerated by the well woman undergoing CD; 
however, these can cause significant harm in those not able to compensate adequately, like 
cardiac or hypovolemic patients. Studies comparing bolus administration versus infusion have 
consistently showed that the haemodynamic changes are not profound when oxytocin is given 
as an infusion (27). Oxytocin can also cause myocardial ischemia, arrhythmias, headache, 
nausea, flushing and vomiting. Also of concern is that prolonged use of high doses of oxytocin 
in infusions may cause minor activation of vasopressor and antidiuretic hormones which may 
produce water intoxication, hypotension and hyponatremia (28,29). 
Spinal anaesthesia is the most commonly used mode of anaesthesia for obstetrics in primary 
and regional hospitals in South Africa (30). Hypotension and bradycardia are common side 
effects of spinal anaesthesia as a result of anaesthetized sympathetic innervation (31). This 
hypotension may be potentiated by oxytocin use, especially at high doses, and blood loss that 
occurs at CD. 
There have been reports from the UK of deaths that were attributed to oxytocin; these, however, 
were in haemodynamically unstable women (32). In some of the cases reviewed in the UK 
incidences of healthcare providers giving higher than recommended doses of oxytocin were 
encountered (33). These side effects can be counteracted by infusing oxytocin with isotonic 
solutions like ringer’s lactate and normal saline. 
2.2.2 International guidelines on oxytocin use at CD 
The Royal College of Obstetricians and Gynaecologists (RCOG) and the British National 
Formulary in the UK recommend for PPH prophylaxis at CD, that 5 IU oxytocin be given by slow 
intravenous injection (34,35).  
In the United States of America, the American College of Obstetricians and Gynaecologists 
(ACOG) does not specify the agent, dose or route of administration for PPH prophylaxis at CD, 
but rather advises that individual obstetric units should have guidelines for the routine 
administration of uterotonics in the immediate postpartum period (36). For acute medical 
management of PPH caused by uterine atony, ACOG state that the choice of the uterotonic 
agent, bar any known contraindications, is at the discretion of the practitioner because no one 
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agent has been shown to be superior to another for the treatment of uterine atony. With specific 
regard to oxytocin, ACOG recommends an infusion of oxytocin 10 – 40 IU in 500 – 1000 ml as a 
continuous infusion or 10 IU IMI (36). 
The Society of Obstetricians and Gynaecologists of Canada (SOGC) recommends oxytocin for 
vaginal deliveries while carbetocin 100 micrograms IVI slow infusion over one minute is 
recommended for PPH prevention at CD and in women with at least one risk factor for PPH 
(37).  
The Royal Australian and New Zealand College of Obstetricians and Gynaecologists 
(RANZCOG) recommends oxytocin as the prophylactic uterotonic for both vaginal and CD, 
however neither the dose nor route is specified (38).  
The WHO recommends either IM or IV 10 IU oxytocin for the prevention of PPH after vaginal 
delivery; and intravenous oxytocin for the treatment of PPH by slow bolus at CD, but does not 
specify the dose (22). 
The use of 5 IU oxytocin bolus, as recommended by the RCOG, has been suggested to be too 
high by some authorities, given the above side effect profile of the drug. Doses as low as 0.5 – 3  
IU have been found to be sufficient to cause adequate uterine contractions (39,40).  
In South Africa, the dosing of oxytocin and indeed a stepwise approach to administration of 
uterotonics at CD was described in the PPH monograph (8) and updated after consensus was 
reached among anaesthetists and agreed upon with obstetricians (10). It is reproduced in Table 
2.1 below. The recommendation at CD is for oxytocin 2.5 IU IVI to be given as a slow bolus over 
30 seconds which should be repeated if the uterus remains atonic. It should be followed by 7.5 
IU IVI in the remaining IV fluid as an infusion. A further infusion of 20 IU in a 1000 ml running at 
125 ml over eight hours would then be administered as a prophylactic postpartum infusion. The 
South African guideline also gives an option for intramuscular use of oxytocin at CD and 
syntometrine post CD in women with no contraindications to the latter and in situations where IV 
infusions cannot be maintained.  
In one trial, the administration of an oxytocin bolus and subsequent infusion have been found to 
be superior to an oxytocin bolus only in that there was no need for additional uterotonic use in 









(Suitable for units equipped with 
volumetric pumps, syringe drivers 
and trained anaesthetists) 
Option 2  




1. Oxytocin 2.5iu ivi slow bolus (over 
30 secs) 
2. Oxytocin 7.5 iu in remaining ivi fluid 
to running in 
3. Oxytocin infusion 
20iu/1000mls@125mls/hr 
1. Syntometrine ® 1 amp in 
left deltoid after delivery 
baby (be aware of 
contraindications) 
If contraindicated 
Syntocinon 10 iu in left 
deltoid after delivery baby 
(repeat at 4 hours in ward) 
Step 2: 
Ongoing uterine 
atony at 3 
minutes 
1. Repeat oxytocin 2.5iu ivi slow bolus 
(over 30 secs) 
2. Oxytocin infusion 
20iu/1000mls@125mls/hr 
Ensure total misoprostol dose 




1. Ergometrine 0.2mg ivi slow bolus 
repeated up to 1.0 mg 
Or 
Syntometrine 0.1mg/1iu ivi slow bolus 
(over 30 secs) repeated up to 0.5 
mg/5iu 
2. Oxytocin infusion 
40iu/1000mls@125mls/hr 
3. Cyclokapron 1g ivi 
4. Check coagulation profile 
5. Administer blood and FDP/FFP  
1. Repeat IMI dose in Right 
deltoid 
2. Cyclokapron 1g ivi 
3. Check coagulation profile 
4. Administer blood and 
FDP/FFP products 





1. Ensure total misoprostol dose is 600 
mcg in last eight hours 
2. Consider intramyometrial 
Prostaglandin F2 alpha (250 mcg)  
3. Check fibrinogen levels 
4. Follow massive transfusion protocol 
Pack uterus and transfer 
 
Most international guidelines, including the South African guidelines, recommend a 20 – 40 IU 
oxytocin infusion as the first measure for treating PPH due to uterine atony 
(8,10,11,21,30,31,32). In the setting of acute postpartum haemorrhage, oxytocin is ideal since it 
has a fast onset of action of three to five minutes, when given intravenously (42) while its half-




While oxytocin is the drug of choice for PPH prophylaxis, one of its main drawbacks is the 
requirement for strict cold chain, need for parenteral administration, need for sterile equipment 
and trained personnel, thus making it unsuitable for many low resource settings. An alternative, 
second line uterotonic in low resource settings is misoprostol. Misoprostol is a prostaglandin E1 
analogue that is used off label to cause uterine contractions. Initially registered for 
gastrointestinal peptic ulcer disease caused by nonsteroidal anti-inflammatory use, misoprostol 
has widespread evidence based use in terminations of pregnancy, induction of labour, and can 
be considered in the treatment and prophylaxis of PPH. Evidence shows it is inferior to oxytocin 
when given both for PPH prophylaxis and treatment (43). Its main advantage is ease of use, no 
need for the cold chain, wide availability, low cost and no need for special equipment or 
specialised personnel. However, its side effect profile includes shivering which can occur in up 
to 75% of recipients and raising of maternal temperature (28,44). The onset of action of 
misoprostol given orally is eight minutes, while by other routes it is even slower (11 minutes, 20 
minutes, 100 minutes for sublingual, vaginal and rectal, respectively) (45), however it has longer 
duration of action, up to four hours when administered rectally and vaginally. This long duration 
of action certainly has advantages for areas where postpartum monitoring of patients is not 
ideal. Poor monitoring of patients postpartum by nursing personnel has been identified in 
previous Saving Mothers Reports as one of the contributing factors in PPH related deaths. 
2.4 Carbetocin 
Carbetocin, 1-desamino-1-monocarbo-(2-O-methyltyrosine)-oxytocin, is a synthetic oxytocin 
analogue (46) which has a longer half-life of 40 minutes compared to oxytocin. It is indicated for 
PPH prophylaxis at CD after delivery of the placenta and can be administered either 
intravenously or intramuscularly at a dose of 100 micrograms. Rhythmic uterine contractions 
last 60 minutes after IV administration and 120 minutes after intramuscular administration (47). 
The side effect profile of carbetocin is similar to that of oxytocin and randomised controlled trials 
comparing the two show that one dose of parenteral carbetocin is as effective as an infusion of 
continuous oxytocin in maintaining uterine tone, and is more reliable than an oxytocin infusion 
which is difficult to maintain with limited staff numbers (48). Because of the prolonged duration 
of action, monitoring of patients postoperatively on carbetocin is not labour intensive. A new 
formulation of carbetocin that is stable at room temperature and thus does not require 
refrigeration has been under investigation in a large randomized non inferiority trial to compare it 
with oxytocin (CHAMPION trial) (49). The recently published results show that heat stable 
carbetocin is not inferior to oxytocin in preventing blood loss of 500 ml or in the use of additional 
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uterotonic agents. It is also not inferior in preventing blood loss ≥ 1000 ml, although the study 
was not powered for this finding because of low rates of this event.  
2.5 Ergometrine  
Ergometrine is an ergot derivative that has agonist properties at alpha adrenergic receptors thus 
causes sustained uterine contraction. It has a short onset of action within a minute of 
intramuscular injection and has a long half-life of up to two hours. It is indicated for the 
prophylaxis and treatment of PPH, however it has side effects which have led to a reduction in 
its use. These include nausea and emesis, and it is contraindicated in hypertensive and cardiac 
patients. However, where no contraindication exists it is very effective and is the second line 
agent for treating uterine atony in the South African protocol. Ergometrine is often combined 
with oxytocin as syntometrine (5 IU oxytocin and 0.5 mg ergometrine) and this combination has 
been found to be superior to oxytocin administered alone (50). The time of onset of 
syntometrine is shorter when administered intramuscularly than that of ergometrine alone and it 
has a longer duration of action. Syntometrine compared to oxytocin alone, has been found in a 
randomised controlled trial on CD PPH prophylaxis in Pretoria, South Africa to reduce by more 
than half the need for postpartum transfusion based on clinical need (51). Syntometrine or 
ergometrine can also replace a post CD oxytocin infusion in low resource settings where there 
is no capacity to maintain an infusion in a postnatal ward. 
2.6 Tranexamic acid 
The use of tranexamic acid, a systematic antifibrinolytic medication which can be administered 
IV for the prevention of PPH, was recently investigated in the World Maternal Antifibrinolytic 
(WOMAN) trial. Results show that there is a significant reduction in the number of deaths from 
PPH and in the number of laparotomies performed to control bleeding in women given 
tranexamic acid early (within three hours) after delivery compared to placebo (52). Also of note, 
is that thromboembolic events in both arms of the WOMAN trial were similar. Tranexamic acid 
has been used in non-obstetric trauma patients to prevent fibrinolysis and results of a large 
CRASH 2 trial showed a reduction in mortality in this patient group (53). A systematic review of 
tranexamic acid use preoperatively before skin incision showed a significant decrease in blood 
loss with no differences in thromboembolic episodes between controls and the treatment arms. 
The WHO has in the past (2012) recommended the use of tranexamic acid when uterotonics fail 
to control bleeding, with a caveat that the recommendation was based on moderate strength 
evidence. With the recent release of the WOMAN trial results, there is now more robust 
evidence to incorporate parenteral tranexamic acid into obstetric protocols for PPH treatment 
(54). More work still needs to be done on the use of oral tranexamic acid for use in less well-
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resourced settings. At the time of conducting this study, TXA use for PPH was not widespread 
in South Africa and it was not available at primary care.  
2.7 Surgical technique 
Haemorrhage at or after CD can also be prevented by good surgical technique at the primary 
surgery. Care should be taken with incisions on the abdomen and uterine walls to avoid 
extension of incisions and to ensure good hemostasis. Uterine incision should be extended by 
blunt dissection instead of sharp extension because of decreased blood loss, decreased 
postpartum haemorrhage and need for transfusion. Placental delivery should be by controlled 
cord traction instead of manual removal, with a uterotonic given to all women at placental 
delivery. Where there is poor response to uterotonics and tranexamic acid, insertion of uterine 
compression sutures such as the B-Lynch suture, assist in maintaining uterine compression. 
Uterine balloon tamponade is valuable where there is placental site bleeding such as in cases of 
placenta previa (9). Uterine artery ligation is another surgical measure that reduces uterine 
bleeding allowing conservation of the uterus. If bleeding is noted after the CD, a relook 
laparotomy is strongly encouraged and should be undertaken. The goal of the surgeon at the 
relook laparotomy is to try and stop bleeding by using the least invasive methods possible 
(uterine artery ligation, balloon tamponade, compression sutures) progressing eventually to 
hysterectomy. However, the surgeon should not feel compelled to go through all the different 






Chapter 3:  Aims and Objectives 
3.1 Overall aim 
The aim of this study was to perform an audit of prophylactic and therapeutic use of uterotonic 
medications at CD.  
3.2 Specific primary objectives 
 
1. To describe the uterotonic drugs, dosages and routes of administration given for PPH 
prophylaxis to women having CD. 
2. To describe the uterotonic drugs, dosages and routes of administration given for 
management of PPH in women having CD. 
 
3.3 Specific secondary objectives  
 
3. To determine the proportion of CD women who developed postpartum haemorrhage, 
and its management. 
4. To determine how MMH practices adhere to the national recommendations on uterotonic 








Chapter 4:  Methodology 
4.1. Study design 
This was a retrospective descriptive clinical audit. 
4.2. Study setting  
The study was conducted at MMH in Cape Town. MMH is a 130 bed, regional/secondary level 
hospital in the Metro West Health District that offers maternity and neonatal services to a 
catchment area served by five midwife obstetric units (MOUs). These currently are False Bay, 
Gugulethu, Mitchell’s Plain, Hanover Park and Retreat. MMH conducts on average 850-900 
deliveries per month with 45% of these being CDs (57). As a teaching hospital, obstetric 
services are consultant led with registrars/residents, medical officers and junior doctors (interns, 
community service doctors) in training making up the bulk of the medical team. The majority of 
the CDs are performed by the registrars and medical officers; as is usually the case in 
comparable South African hospitals. All non-specialist doctors need to be accredited by a 
consultant before they can perform CDs independently. A consultant obstetrician is always 
available, onsite during daylight hours, and afterhours on standby off site to come to assist with 
difficult CDs and perform peripartum hysterectomies where necessary. Similarly, consultant 
anaesthetists are on site during the working day to assist anaesthetic registrars and medical 
officers who perform the majority of anaesthetics and are available for problems after hours.  
The population profile served by MMH is diverse. The women are from different socioeconomic 
backgrounds, mainly low to middle income and of varying racial, religious and national 
backgrounds.  
Obstetric care in South Africa is provided free of charge in the Public Sector. On recognising 
that they are pregnant, women are encouraged to ‘book’ or register for antenatal care at an 
MOU or Basic Antenatal Clinic (BANC) nearest to them. MOUs, as the name suggests, are 
midwife run and led, with support outreach visits from their referral hospitals. Basic obstetric 
care and deliveries are performed at the MOUs. Any complicated women either antenatally, 
intrapartum or postpartum are referred onwards to higher levels of care as per local protocols 
that are widely distributed in the MOUs. Secondary level referrals are sent to MMH which may in 
part explain the high CD rate described above. Women with previous CD, as an example, are 
managed at the MOUs until the 36th to 37th week of gestation whereupon they are referred to 
level 2 for further care. Those requiring sub-specialist obstetric care, input from other medical 
disciplines or critical care are stabilised at MMH and then referred to the tertiary obstetric unit at 
Groote Schuur Hospital (GSH). 
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4.3. Study population 
Inclusion criteria: The study population was women who delivered by CD performed at MMH 
during June and July 2017. February and August were excluded as potential months because 
they are the times when new obstetric and anaesthetic doctors commence at MMH and may not 
yet be familiar with protocols. The study population included both elective and emergency CDs.  
Exclusion criteria: Women having vaginal delivery during the same time period. 
4.4. Data collection 
The cases were identified retrospectively from the theatre register, and the women’s files were 
retrieved from the medical records of MMH and also from GSH if the women had any reason to 
be referred there postoperatively. 
The following data were abstracted from the files and entered onto a purpose designed data 
collection sheet: basic demographic data; indication for CD; anaesthetic and operative details; 
duration of the surgery (‘knife to skin’ to ‘last stich’); type of uterotonic drug used for prophylaxis; 
type of uterotonic drug used for treatment; estimated blood loss; operative and short term 
postoperative complications (Appendix A). The data collection was performed by the principal 
investigator who obtained the required data from the anaesthetic form which is completed by the 
anaesthetist during the operation, the operating notes completed by the surgeon and from the 
women’s maternity care booklet. The maternity care booklet is a standard national document in 
which the events/interactions during the pregnancy are documented from booking to postnatal 
period and this remains in the hospital folder at women’s discharge.  
PPH for the purposes of this study was defined as bleeding at or after CD using the following 
indicators: 
Blood loss more than 1000 ml as estimated by the operating team and/or:  
a) Additional surgical measures such as uterine compression sutures or balloon tamponade 
are required to control bleeding;   
b) Relook laparotomy with or without hysterectomy is required; 
c) Blood/blood product transfusion are administered (excluding blood transfusion 
administered intra-  or postoperatively because of chronic anaemia). 
In order to evaluate the use of uterotonics at CD at MMH, the observed use was compared with 
the sequential steps for prevention and treatment of haemorrhage outlined in the national 
consensus recommendation in Table 2.1 of the literature review (Chapter 2). 
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4.5. Study sample size 
The number of caesarean deliveries performed at MMH ranges from 300 to 400 per month as 
seen from previous studies (57,58). The sample size was calculated with the help of a free 
online sample size calculator for clinical audits (http://www.raosoft.com/samplesize.html 
accessed 27/07/2017 = 357) (59). A margin of error of 5% was accepted, confidence interval of 
95%, population of 5000 being the number of caesarean deliveries per year at MMH, and a 
response distribution of 50%. For comparison purposes, different online calculators were used. 
www.wrha.mb.ca/ extranet/eipt/files/Sampcalcaudits.xls (60), www.uhbristol.nhs.uk/files/ nhs-
ubht/sample_size_calculator.xls (61). Sample sizes were 303 and 304 respectively. A sample 
size of 310 was planned for and it was thought that this could be achieved in one month. 
The medical records department at MMH was understaffed and had very limited personnel for 
the second half of June so the folders retrieved were for the first two weeks of June and the first 
two weeks of July. 
4.6. Data analysis 
This was done by the principal investigator with the co-supervisor. Data were entered onto 
Microsoft Excel and STATA (StataCorp) spreadsheets and the analyses were mostly descriptive 
with frequency calculations.  
4.7. Ethics 
Permission to conduct the study was obtained from the Department of Obstetrics and 
Gynaecology Research Committee and the facility (MMH). In addition, ethics approval was 
obtained from the University of Cape Town Human Research Ethics Committee (Appendix C). 
The women’s data were anonymized, treated confidentially and held securely by the principal 
investigator in a password protected electronic device. 
Patient information was  held in confidence as per the 1964 World Medical Association 
Declaration of Helsinki as it pertains to biomedical research (62). This was a retrospective folder 





Chapter 5:  Results 
5.1 Data analysis 
A total of 319 folders were reviewed for this study. There were 404 CDs (both electives and 
emergencies) performed in MMH for the month of June 2017. The study sample was intended 
to be drawn from June 2017 only, however due to problems described above with clerical staff 
at MMH medical records, only 186 folders up to 15 June 2017 could be accessed. The number 
obtained did not meet the sample size required, so folders from CD performed in the first two 
weeks of July 2017 were accessed to make up the shortfall of 133. 
5.2 Patient characteristics 
The mean age (± SD) was 28 (±6.2) with a range of 14 to 46 years, median gravidity 2 (±1) 
(range 1 to 6) (IQR 2), median parity 1 (range 1 to 4) (IQR 2), see Table 5.1. The mean pre-
operative haemoglobin (Hb) was 11.5 (±1.4) g/dl (Table 5.1). 
Pre-existing medical or obstetric comorbidities were found in 227 (71.2%) women who had 
either one or more of the conditions tabulated in Table 5.2. Only one (0.3%) woman had severe 
anaemia of 7.3 g/dl preoperatively. A raised body mass index (BMI) in this study was taken as 
anything above 25 kg/m2, and over half of the study population, 175 (54.9%), was overweight or 
obese.  
There were 96 (30.1%) nulliparous women in the study while 223 (69.9%) women were parous. 
Among the parous women, 126 (56.5% of parous women and 39.4% of total study group) had 
had a previous CD, these being: 79 (25%); 45 (14%); and 2 (1%) with one, two or three 
previous CDs, respectively.  
There were 67 (21%) women who were HIV positive and 65 (97%) of them were on 
antiretroviral therapy. There were no treatment records for the other two women. HIV viral load 
was suppressed (< 100 copies/ml) in only 49 (75%) of those of treatment. 
Table 5.1:  Patient characteristics (n = 319)  
 Median/Mean Lowest Highest 
mean Age (years) 28 14 46 
median Gravidity 2 1 6 
median Parity 1 0 4 
mean Pre-op Hb* 
(g/dl) 





Table 5.2:  Obstetric and medical co-morbidity (n = 319)  
Condition  Number % 
Previous CD 126 39.4% 
HIV positive 67 21% 
Hypertension (PET + CHPT) 47 14.7% 
Asthma 8 2.5% 
BMI > 25 175 54.9% 
Some women had more than one comorbidity. 
5.3 Details of caesarean deliveries 
There were 239 emergency CDs (75%) and 80 elective CDs (25%). Indications for CD were 
grouped into maternal (e.g. previous CD), fetal (e.g. pathological CTG) and placental (e.g. 
placenta previa) and specific indications for CD were then detailed (see Figures 5.1 and 5.2). 
There were 172 (54%) CDs performed for fetal reasons and 141 (44%) for maternal reasons. 
Fetal distress/pathological CTG was the most common specific indication for CD with 128 
(40%). Previous CD was the second most common specific indication; this included patients 
with one previous CD who had an unsuccessful attempt at a vaginal delivery after CD (VBAC), 
those who declined to attempt a VBAC or had more than one prior CD. Infrequently occurring 
indications like retained second twin, previous obstetric anal sphincter injury, placenta previa, 
intrauterine growth restricted fetuses, placenta previa and eclampsia were grouped together as 
‘other’ in Figure 5.2. This latter group accounted for 3% of all indications for CD. 
 













Figure 5.2:  Specific indications for caesarean delivery (n = 319) 
APH: antepartum haemorrhage, Abn Pres: abnormal presentation, IOL: Induction of labour, Prev 
CD: previous caesarean delivery, Path CTG: pathological cardiotocograph, ‘Others’: refers to a 
number of indications in this study that occurred twice or less (included previous third degree 
tears, retained second twin, eclampsia, fetal growth restriction, placenta praevia and cord 
prolapse). 
There were 167 (52%) CDs performed during the day shift and 152 (48%) after 4 pm, when 
consultant staff were off site. (Note that there was no distinction between weekdays and 
weekends). The obstetric registrars did the majority of the operations 201 (63%) while medical 
officers did 118 (37%). None of the CDs were performed by consultant staff. The duration of 
surgery (incision to last suture) was 20 to 40 minutes in 210 (66%) operations, while 38 (12%) of 
the operations were performed in under 20 minutes and 71 (22%) over 40 mins. 
5.4 Anaesthesia 
Spinal anaesthesia was performed for 283 (89%) of the operations. This number rose to 92% if 
failed spinals (9 women, 2.8%) that were converted to general anaesthesia are included. 
General anaesthesia was used in 26 women (8%). There were no adverse complications or 
deaths related to anaesthesia. Only one woman had a ‘high spinal’ leading to maternal 
tachycardia. 
  




APH Macrosomia  ''Others'' Failed IOL Abn Pres Prolonged
labour
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5.5 Surgical problems documented at CD 
The operative procedure was described by the surgeons in their operation notes to be easy/ 
uneventful in 256 (80.3%) women and a surgical problem was described in 63 (19.7%). The 
most commonly encountered surgical difficulties described by the surgeons were adhesions in 
25 (7.8%) women due to previous CD, and uterine atony documented in 24 (7.5%) women. 
Uterine atony was diagnosed by uterine palpation for tone at CD. These difficulties were 
described or encountered by all ranks of surgeons and were dealt with either by the same 
surgeon (therefore longer operating time) or a senior doctor/consultant was called in to assist. 
Obesity/raised BMI was documented as a factor in operative difficulty in five cases (1.6%). 
Other reported difficulties were: difficult delivery of the fetus and uterine incision extending 
laterally, see Table 5.3. (N.B.: excessive blood loss is described separately in Table 5.4). 
Table 5.3:  Surgical problems described at CD (n = 63, 19.7%)  
 Frequency* Percentage %** 
Adhesions 25 7.8 
Uterine atony 24 7.5 
Difficult fetal delivery 7 2.2 
Uterine incision extended 
laterally 
5 1.6 
Obesity 5 1.6 
*Three women had more than one factor responsible for surgical difficulty hence frequency > n. 
**Percentages use 319 as the denominator. 
 
Out of the 319 women operated on, three required additional surgical measures – one uterine 
compression suture (B-Lynch) and two had multiple haemostatic sutures secondary to uterine 
atony and uterine trauma/tears, respectively. None had balloon tamponade and none required a 
hysterectomy.  
5.6 Estimated blood loss 
Estimation of blood loss at MMH is done by the anaesthetist who visually inspects soaked 
abdominal swabs, blood (invariably mixed with liquor) in the suction bottle and any blood on the 
operating table linen. The average blood loss in this study was 487 ml (± 220) with a range of 
100 to 2000 ml (see Table 5.4 and Figure 5.3). Estimated blood loss of ≥ 1000 ml occurred in 13 
(4.1%) patients, while 218 (68%) had EBL of ≤ 500 ml. Haemodynamic status changes 
(hypotension and tachycardia) were documented in three women. One woman was transfused 
2U packed red cells after an EBL of 1200 ml. She later developed an ileus for which she was 
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referred to a tertiary hospital. This resolved spontaneously while at GSH and she was referred 
back to MMH. There was only one patient with an EBL of 2000 ml.  
Table 5.4:  Blood loss estimation (n = 319)  
 
 
Figure 5.3:  Scatter diagram showing estimated blood loss in the study (n = 319) 
The most frequently occurring EBL was 400 ml. 13 patients had EBL > 1000 ml. 
 
Of the 13 women with blood loss >1000 mls, there were five who had adhesions, four who had 
uterine atony, five with uterine tears, and one had difficult fetal delivery (she had two previous 
CDs, uterine atony, and adherent placenta and she subsequently required a uterine brace 
suture). (N.B.: Some women had more than one issue hence count exceeds 13). Eight of these 
13 had a BMI > 25 kg/m2 but their obesity was not documented as a factor in causing difficult 
surgery. Twelve women had an emergency CD, and three of the 13 women had general 
anesthesia. The duration of surgery was more than 40 minutes in 11 of the 13 women. 
It was noted that 20 of the 24 women (83.3%) with documented uterine atony and 20 of the 25 























study subjects 1 - 319
EBL pattern
Est blood loss 
(ml) 
≤ 500 501 – 999 1000 – 1499 1500 - 1999 >2000 
Frequency 218 88 11 1 1 
Percentage (%) 68 28 3 0.3 0.3 
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5.7 Uterotonic use 
This will be described according to the steps in the recommended protocol for South Africa as 
described in Table 2.1, (page 8). 
5.7.1 Step 1.1 (initial oxytocin 2.5 IU bolus) 
75 (23.5%) of the 319 patients received 2.5 IU oxytocin IVI initial bolus as per protocol, while 
227 (71.1%) got other doses (Figure 5.4). There were 17 (5.3%) women for whom there was no 
record of any initial bolus being given. There was no documentation of intramuscular 
prophylactic administration of oxytocin or syntometrine for any woman.  
 
Figure 5.4:  Number of patients who received 2.5 IU oxytocin slow IVI bolus (n = 319) 
Only 23.5% of the study group received 2.5 IU. 
The 2.5 IU bolus was more likely to be given during the working day than after hours 65% 






















Figure 5.5:  Comparison of oxytocin bolus usage between day and night 
 
2.5 IU was more likely to be given during the day than in the evening. The time of the day did 
not influence how the other boluses were given. 
The other different oxytocin boluses given in lieu of 2.5 IU ranged from 1 IU to 7.5 IU IVI and are 
shown in Table 5.5. Three (3) IU of oxytocin either as a single dose or in a variety of divided 
doses (‘1+1+1’ or ‘1.5+1.5’) was the initial bolus that was most frequently given, 169 women 
(53%). It was noted that all initial IV boluses (except for one of 7.5 IU), were less than 5 IU. 
Table 5.5:  Oxytocin prophylactic boluses administered (n = 319)  
Oxytocin bolus (IU) Frequency Percentage (%) 
2.5 75 23.5 
3 139 43.6 
‘1+1+1’ 16 5 
‘1.5+1.5’ 14 4.1 
2 36 11.3 
1 5 1.6 
‘1+1’ 2 0.6 
4 2 0.6 
7.5 1 0.3 
Nil 17 3.2 
Nine unique oxytocin boluses were given in the study. 
5.7.2 Estimated blood loss and initial oxytocin bolus 
The mean EBL in the group (75) who got 2.5 IU was 488 (±158) ml while for 42 women who got 
















Among the 24 patients with documented atony, 7 (29.2%) were given initial 2.5 IU IVI, while 11 
(45.8%) got alternative doses (2 IU for one patient; 3 IU for ten patients). Six (25%) did not get 
initial bolus oxytocin, or if given it was not documented. 
5.7.3 Steps 1.2 and 1.3 (intraoperative and postoperative oxytocin infusion) 
Step 1.2 refers to 7.5 IU infusion which is to be administered intraoperatively and Step 1.3 to the 
20 IU prophylactic postoperative infusion. However, reading from the patient files it was not 
possible to determine whether the infusions were commenced intraoperatively or 
postoperatively; or for prophylaxis or treatment, so these steps have been combined. 
Eighteen patients (5.6 %) received oxytocin 7.5 IU as an infusion in the remaining fluid as per 
protocol. Of the 75 patients who got the initial 2.5 IU bolus, 17 of them got 7.5 IU infusion. Other 
patients got different oxytocin doses for infusions as described below. 
There were 212 patients (66.5%) who received 17 alternative doses of oxytocin infusion which 
ranged from 2.5 IU to 24 IU, see Table 5.6. Some of the other infusion doses not depicted in 
Table 5.6 were: 2.5, 4, 5, 8, 9, 15, 16 and “infusion”.  
There was no documented evidence that 89 (26.6%) patients got any oxytocin infusion at all. 
The oxytocin for infusion, when given, was diluted in a variety of volumes of fluid – 500 ml to 
1000 ml of modified ringers lactate (mRL). Twenty (20) IU of oxytocin in a litre of mRL was the 
most commonly prescribed infusion dose in 65 (20.4%) patients.  
There was no documentation of volumetric pumps or dial flows being used to ensure an infusion 
rate of 125 ml/hr as per protocol. 
Table 5.6:  Oxytocin infusion prophylactic doses used in the study (n = 319)  
Oxytocin dose (IU) Frequency Percentage % 
20 65 20.4 
22 11 3.4 
18 13 4.1 
17.5 24 7.5 
17 14 4.4 
12 11 3.4 
10 33 10.3 
7.5 18 5.6 
 7  10 3.1 
0 89 27.9 




5.7.4 Continued prophylactic oxytocin infusion in the ward 
There was no instruction for the nursing staff by the obstetric doctor or anaesthetist to continue 
oxytocin prophylaxis in the ward in 270 (85%) of the patients’ prescription charts. The order was 
documented in only 49 (15%) of women and the dose ordered was 20 IU in a litre to run over 
eight hours. There was documented evidence, however, as per nursing notes, of 103 (32%) 
women arriving in the ward with oxytocin infusion running. This means that, for these 103 
women, an oxytocin infusion was commenced without any documentation or instruction in the 
prescription chart or anaesthetic record.  
5.7.5 Step 2.1:  Initial treatment of PPH/uterine atony by repeat IV bolus 
Repeat bolus of oxytocin (to be given for ongoing uterine atony at three minutes) was given to 
15 (5%) patients; however, in only three (3) women was the recommended 2.5 IU IVI repeat 
dose given. Other repeat doses were 2, 3 and 7.5 IU IVI bolus.  
The reason for repeating the bolus dose was not documented in the anaesthetic charts. 
However, a perusal of surgical notes indicates that uterine atony was documented in only two 
patients where a repeat bolus was given. The mean blood loss in these patients was 650 ml 
(300 – 1500 ml). 
5.7.6 Step 3:  Further medical treatment of PPH/uterine atony 
This step involves oxytocin infusions, IV or IMI administration of oxytocin or syntometrine, and 
other medications. 
In terms of the oxytocin infusions, it was not always clear from the women’s files whether they 
were given prophylactically or therapeutically. 





Table 5.7:  Summary of the uterotonic management of the 13 patients with PPH and the 


































7 11 0 1 1 15 3 13 1 
Alt: alternate; Miso: misoprostol; TXA: tranexamic acid; Synto: syntometrine. None of the patients in the 
study got prostaglandin F2alpha. 
*It was not possible to distinguish between prophylactic oxytocin infusion and treatment infusion. 
In the PPH group (n=13), 12 got a low dose IV bolus and of these three had a repeat oxytocin 
bolus. There were ten who had a 20 IU oxytocin infusion, two who had syntometrine, five 
misoprostol and one tranexamic acid.  
Considering the 24 women with uterine atony (of whom four had PPH), 18 got a low dose IV 
bolus and of these two had a repeat oxytocin bolus. There were six women who received no 
initial IV bolus. There were 15 who had a 20 IU oxytocin infusion, two who had syntometrine, 13 
misoprostol and one tranexamic acid.  
In addition to the additional treatments described above, a further 17 (5.3%) patients were given 
misoprostol while another seven (2.2%) got syntometrine yet they were not documented to have 
either PPH or uterine atony. 
5.8 Additional surgical measures and further treatment 
Three women required additional surgical measures. This included one woman who required 
uterine compression suture (B-Lynch) as a result of uterine atony and an adherent placenta 
following a difficult fetal extraction with blood loss estimated to be 1000 ml and two patients who 
had multiple haemostatic sutures secondary to uterine atony and uterine trauma/tears 
respectively. None had balloon tamponade and none required a hysterectomy. 
In addition, no woman needed a re-look laparotomy, or died (at least in the first three or so days 
post operation). Two women were referred to Groote Schuur tertiary hospital for further 
management; one was for management of eclampsia while the second was for ileus (described 
above) and not for haemorrhage related complications.   
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Chapter 6: Discussion 
6.1 Introduction 
This study of 319 patients having CD at a secondary level hospital showed that the majority 
(75%) of the CDs were done as emergencies by registrars and medical officers with a 
documented PPH rate of 4.1% and no major morbidity or mortality.  
6.2 Prophylactic oxytocin bolus at CD 
The recommended oxytocin protocol was not always adhered to in this study. Lack of, or poor 
documentation was noted in 5% of women. 
Only 23.5% of the women were given the recommended 2.5 IU of intravenous slow bolus 
oxytocin after delivery of the fetus. The other 227 (71%) women who were not given 2.5 IU still 
received low dose oxytocin as a bolus (≤5 IU) which is lower than the recommendation of the 
RCOG and other workers in this area (34,40). This in effect means 301 (94%) of women in this 
study received bolus oxytocin less than 5 IU IV. 
The rationale for giving doses of 2.5 IU in the national recommendation arose from studies 
showing it was the optimal dose that balanced safety with efficacy (39).  
The most commonly administered oxytocin bolus in this study was 3 IU slowly IVI. The rationale 
for this is unclear, given that none of the national guidelines advocate for the use of this dose. 
Perhaps it all stems from the ease of drawing up 3 IU as opposed to 2.5 IU. An interesting 
finding arising from this study was that 2.5 IU was statistically significantly more likely to be 
given in daytime compared to afterhours, again perhaps due to the ease of drawing up the 3 IU 
dose. It is possible that the presence of more anaesthetic staff, including consultant 
anaesthetists, during the day could influence the adherence to protocol as opposed to at night 
time when a lone anaesthetist, sometimes a junior registrar just starting their rotation, runs the 
service alone. It is a shortcoming of this study that the rank of anaesthetic provider was not 
recorded as it was for obstetric doctors. This should be taken into consideration when the audit 
is repeated at other sites.  
Some anaesthetists preferred to give the 3 IU in divided aliquots either ‘1+1+1’ or ‘1.5 + 1.5’, 
perhaps as a way of reducing the side effects of oxytocin, as evidenced by a few patients with 
hypotension in this study. The time interval between administering these could not be 
established from the anaesthetic chart. It was also difficult to tell if these ‘1+1+1’ could be 
characterised as repeat boluses. The ‘1+1+1’ regimen was given to 16 (5.2%) while the ‘1.5 + 
1.5’ was given to 12 patients (3.9%).  
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Although this study showed that the 3 IU bolus was the most commonly given prophylaxis at CD 
which is a departure from the national recommendation, the difference is extremely small and 
the majority of dosages (94%) given were less than 5 IU and thus constitute low dose boluses. 
The finding that a low PPH rate at CD with no severe morbidity or mortality can be achieved 
with low dose prophylactic oxytocin IV boluses is important. Moreover, it is in the context of the 
majority of CDs being emergencies and all being done by registrars or medical officers. The 
findings thus allay concerns that have been expressed by some constituencies in South Africa 
that the high levels of maternal mortality due the BLDACD in South Africa may be due to 
national recommendations for IV boluses at CD that are too low.  
6.3 Comparison with other audits on oxytocin boluses 
Despite MMH not fully adhering to protocol, the oxytocin doses used in this study are low 
compared to findings from a similar audit of 139 CD patients done by Tsima et al. (11) in 
Botswana who found very high doses of oxytocin boluses (10 to 20 IU IVI) being used. Tsima et 
al. indicate in their study that there were no local protocols governing the use of uterotonics in 
their setting and thus RCOG and WHO guidelines were the standards of care. However, 
compliance to those protocols was also poor, with only 30% of patients being given 5 IU IV 
bolus as per RCOG. There was no documented use of doses less than 5 IU in the Botswana 
study. 
6.4 Oxytocin bolus dose and associated blood loss 
There was no clear pattern that emerged from this study as to which bolus dose was associated 
with ongoing uterine atony and thus PPH (blood loss 1000 ml or more) because of the small 
number of patients with PPH in this study. Only three incidents of PPH occurred when the initial 
bolus was 3 IU compared to none when 2.5 IU and ‘1+1+1’ were given. It is evident from this 
study that PPH results from multiple factors. Of the patients who did not get the bolus oxytocin, 
none had PPH, only two had documented uterine atony which was managed with misoprostol. 
6.5 Oxytocin infusion 
A little over a quarter of patients in this study did not receive oxytocin infusion, or if given it was 
not documented. The current protocol of oxytocin use indicates that routine prophylactic 
oxytocin infusion be given to all women post-delivery of the fetus. Not giving prophylactic 
oxytocin by anaesthetists could be due to concerns about its side effects thus they would rather 
give it when indicated. This is in keeping with findings by Wedisinghe et al. (63), who did an 
oxytocin user survey in the UK and found that 78.7% of anaesthetists preferred selective use of 
oxytocin, while 21% preferred routine use. A follow up survey by the same group (25), now 
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extended to all countries of the UK and Ireland, also found that there was still wide variation in 
the oxytocin infusion use among obstetricians and anaesthetists; 38 different regimens were 
used to administer an oxytocin infusion. Obstetricians in that same survey also favoured 
selective oxytocin use. The commonest indications cited for infusion use were intraoperative 
haemorrhage, multiple pregnancy, placenta previa, previous PPH and prolonged labour. In 
South Africa, however, Saving Mothers Reports have described high rates of bleeding after CD 
being discovered in postnatal wards where monitoring may be poor (4,5). Thus routine 
postoperative uterotonic use is recommended. If IV infusions are difficult to maintain in 
understaffed postnatal wards, alternatives would be intramuscular syntometrine or oxytocin (9). 
The Canadian guidelines recommend postoperative carbetocin which is given as a single dose 
parenteral injection with a prolonged action. The introduction of a heat stable and cheaper form 
of carbetocin, could be more efficacious and cost saving in the public sector in South Africa 
(51). The CHAMPION trial has shown that heat stable carbetocin is just as efficacious as 
oxytocin (49). 
6.6 Anaesthesia 
This study showed that at MMH the anaesthetic of choice for CD is spinal anaesthetic. It was 
generally well tolerated by the patients with no adverse events associated with its use. This 
finding is dissimilar to Tsima et al. who found that general anaesthetic (GA) was used in 64% of 
patients in their study. GA is a known risk factor for uterine atony leading to PPH. Three women 
in this study with a blood loss ≥ 1000 ml had a GA and two of these had uterine atony. 
6.7 Duration of surgical time 
It is recommended that the ideal duration for performing a CD should be 45 to 60 minutes (64). 
Many junior doctors strive to perform shorter durations of the CD (≤ 10 minutes). Such short 
surgery duration is thought more likely to be associated with morbidity due to lack of care in 
ensuring good haemostasis. It is gratifying to note that despite MMH being an extremely busy 
hospital, the surgeons take time in performing surgery with all of the CDs taking more than 20 
minutes. 
6.8 Patient population 
There were 67 (21%) HIV positive women; of these only two were not on antiretroviral therapy. 
This HIV prevalence is similar to the finding of a prevalence of 18.9% (2015 national data) (65) 
for the Western Cape among women attending antenatal care. Of those on treatment, 73% had 




Fifty-four percent of the women in this study had a BMI > 25. A raised BMI was a factor in 
contributing to operation difficulty and increased blood loss in this study. This is keeping with 
other studies that looked into the subject of obesity and its outcomes in pregnant women in 
South Africa (66). 
6.9 Emergency caesarean deliveries 
Three quarters (75%) of the CDs in this study were emergencies. This is not surprising for a 
regional level 2 hospital like MMH which has a large catchment area and serves as a referral 
centre for several MOUs. Emergency CD is well known to carry higher risk for maternal 
morbidity and mortality compared to elective CD. In this study 12 out of the 13 women with PPH 
had an emergency CD. There were no peripartum hysterectomies or other major morbidity that 
was seen in this study. This is due perhaps to the fact that the majority of women were operated 
on by senior staff (registrars) and experienced medical officers. It is important to note the finding 
that the numbers of women with PPH were less than the numbers with uterine atony which 
attests to prompt recognition and early treatment by surgeons and anaesthetists of the uterine 
atony. Poor surgical technique and inexperienced staff have been found to be factors in many 
confidential maternal mortality reviews, especially at level 1 hospitals in South Africa.  
6.10 Patient outcomes  
The majority of women in this study had an uneventful postpartum course (no adverse peri or 
post-operative complications). One woman was referred to GSH because of eclampsia, while 
another was referred for ileus. 
6.11 Study limitations 
Given that it was a retrospective folder review it was dependent on surgeons and anaesthetists 
documenting outcomes, surgical difficulty and uterotonic use. If it was not documented, it cannot 
be ascertained whether this was a recording error, or it did not occur. Also, the outcomes of 
uterine atony and PPH are subjective and may have been underestimated. Nevertheless, the 
observation of no relook laparotomies, and no severe morbidity or mortality support the finding 
of low reported complication rates.  
Also, the sample size did not allow a correlation between PPH and oxytocin use to be 





Chapter 7:  Recommendations and Conclusion 
7.1 Recommendations 
The study results indicate a need for a more formal method for recording uterotonic use at CD 
and distinguishing whether it is for prophylaxis or treatment. This is particularly necessary for 
single bolus oxytocin doses as well as infusions. This could be incorporated as a checklist or 
text box into the standardised maternity case record which is currently in the process of revision. 
Also, it would be important for the anaesthetic fraternity in South Africa to collectively re-discuss 
recommended dosages for oxytocin prophylaxis at CD. Although at a hospital such as MMH, 
there is consultant anaesthetic supervision, which could allow for some variation among 
specialists, this is not the case at district hospitals where the majority of CDs are performed in 
South Africa by non-specialist surgeons and anaesthetists. At this level there is the need for 
clear standardised protocols for uterotonic use at CD.  
Repeating this study at peripheral district hospitals where there is high maternal morbidity and 
mortality from bleeding at CD is important to determine what is being practised, with the view to 
improving the quality of care. 
7.2 Conclusion 
The national recommended uterotonic protocol is not fully complied with at MMH; however 
alternative low dose oxytocin bolus and infusion regimes are used widely at CD. The finding that 
a low PPH rate at CD with no severe morbidity or mortality can be achieved with low dose 
prophylactic oxytocin IV boluses is important. Moreover, it is in the context of the majority of 
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Appendix A:  Data Collection Sheet 
Data Collection Sheet  
Patient Unique Study Number  




Indication for the CD 0=fetal 1=placental 
2=maternal 
 
Specific indication 0=Path CTG 1=abnormal pres 
2=macrosomia 3=APH 4=Prev CD 5=prolonged 
labour 6=prev myomectomy 7=failed IOL 
8=other; specify ……. 
 
Elective v Emergency 0=Elective 1=Emergency  
Time of CD 0=8am-4pm 1=4pm-8am  
Rank of Surgeon 0=Reg 1= Senior MO 2=Junior 
MO 3=Intern 4=Consultant 
 
Duration of operation (minutes)  0=<20 1= 20-40 
2=>40 
 
Prev C/S 0=0, 1=1, 2=2, 3=3 or more  
Pre-op Hb (g/dl)  
Obstetric or Medical Comorbidity 0=No 1=Yes  
If Comorbidity exists specify: 1=HIV 2=Asthma 
3=raised BMI 4=CHPT 5= IGT 6= Preeclampsia 
 
If HIV 0 = No ARV 1 = On ARV  
If HIV 0 = VL < 100 (suppressed) 1 = VL > 100  
Type of anaesthesia 0=Spinal 1=GA 2= Spinal+GA  
Operative difficulty 0=Easy 1=Difficult  
If Operation difficult specify: 1=adhesions 2=diff 
delivery fetus 3=incision extended laterally 
4=abnormal anatomy 5=obesity 6=other: 
specify……. 
 
PPH 0=No 1=Yes  
EBL (ml)  
Documented uterine atony 0=No 1=Yes  
Uterine trauma/tears 0=No 1=Yes  
Placenta previa 0=No 1=Yes  





Adherent placenta 0=No 1=Yes  
Additional surgical measures 0=No 1=Yes  
If additional surgical measures specify 0=brace 
sutures 1=uterine tamponade; 2=uterine artery 
ligation; 3 =other: specify………. 
 
Peripartum hysterectomy 0=No 1 =Yes  
Intraoperative hypotension * 0=No 1=Yes  
Intraoperative tachycardia ** 0=No 1=Yes  
* Intraoperative hypotension: maternal systolic blood pressure less than 80 % of baseline readings or an 
absolute value of 100 mmHg or both(67) 





Appendix B:  Checklist re. Uterotonic Administration 
Checklist re: Uterotonic administration 
PROPHYLAXIS (intraoperative)  
Oxytocin 2.5 mg IVI bolus 0=No 1=Yes 2=Not 
recorded (NR) 
 
Repeat Oxytocin 2.5 IU IVI given 0=No 1=Yes 
2=Not recorded 
 
If repeat given was reason specified 0=No 1=Yes 
2=Not recorded 
 
Alternative dose given 0=No 1=Yes 2=Not 
recorded. If 1=specify 
 
Alternative route used 0=No 1=Yes 2=Not 
recorded. If 1=specify 
 
  
Oxytocin Infusion  
Oxytocin 7,5 IU IVI in 1 liter 0=No 1=Yes 2=NR  




Other Uterotonics for prophylaxis  
Syntometrine/Ergometrine 0=No 1=Yes 2=NR 
If 1 specify dose and route…… 
 
Misoprostol 0=No 1=Yes 2=NR 
If 1 specify dose and route…… 
 
 
PROPHYLAXIS POST OPERATION 
 
Instructions on prescription chart for nursing to 




Prophylaxis with uterotonics continued in the 
postnatal ward? 0=No 1=Yes 2=NR 
If 1 specify agent, dose and route……… 
 
  
TREATMENT for PPH cases and suspected uterine 
atony 
 
Oxytocin infusion 20 IU in a liter 0=No 1=Yes 
2=NR 
 
Alternative dose given 0=No 1=Yes 2=NR If 1 
specify 
 
Other uterotonics for treatment:  
Syntometrine/Ergometrine 0=No 1=Yes 2=NR 
If 1 specify dose and route 
 
Misoprostol 0=No 1=Yes 2=NR 
If 1 specify dose and route 
 
Tranexamic acid 0=No 1=Yes 2=NR If 1 specify 




Prostaglandin F 2alpha 0=No 1=Yes 2=NR If 1 
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